Browsing Tag
Biogen
18 posts
The inside story behind Samsung Bioepis’ European biosimilar takeover
Samsung Bioepis reclaims control of BYOOVIZ in Europe from Biogen, launching its own brand with a PFS version due in 2026. Read what this means for biosimilars.
Leqembi gains traction in China as commercial insurance innovative drug list expands access for Alzheimer’s patients
Leqembi gains commercial insurance status in China, opening doors for Alzheimer’s patients and transforming access. Find out what this means for BioArctic AB and Eisai.
Will Biogen’s $1bn bet on Vanqua Bio’s oral inflammation drug jumpstart its post-MS future?
Biogen’s $1.06B Vanqua Bio licensing deal signals a strategic shift toward immunology. Explore the roadmap behind this bold preclinical move.
Eisai’s etalanetug earns FDA Fast Track status, signaling new hope in Alzheimer’s therapy
Eisai’s etalanetug gets FDA Fast Track for Alzheimer’s, signaling a major shift toward tau-targeting therapies. Find out what this means for investors.
Biotech layoffs 2025: Prothena joins the wave—What’s driving the restructuring trend?
Explore why Prothena’s layoffs reflect a growing 2025 biotech downsizing trend. What’s causing the wave, and who might be next?
CHMP backs Lecanemab again for early Alzheimer’s as EC reviews approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has reaffirmed its positive opinion on…
Roche’s Gazyva shows superior efficacy in lupus nephritis treatment, Phase III trial data reveals
Roche has announced promising new data from its phase III REGENCY clinical trial, published in the New England…
FDA approves Leqembi maintenance dosing for early Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi (lecanemab-irmb), an…
Biogen’s SKYCLARYS becomes first approved treatment for Friedreich’s Ataxia in EU
In a landmark decision, the European Commission (EC) has authorized Biogen Inc.’s SKYCLARYS (omaveloxolone) for the treatment of…
Biogen reprioritizes Alzheimer’s disease resources, discontinues ADUHELM development
Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s…